Abstract：
BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a chronic condition caused by Human papillomavirus six (HPV-6) and HPV-11 that involves the respiratory tract. Disease severity ranges from mild (hoarseness), through to severe (stridor, respiratory distress and airway emergencies). Africa has the fastest growing and youngest population of all the continents. It also has the greatest burden of cervical cancer. There is an association with infection of the oncogenic HPV strains and the strains responsible for RRP. It is reasonable to conclude that although RRP may be underestimated in low-to-middle-income countries, it poses a considerable health risk to Africa. The primary aim of this project was to assess the suitability of HPV vaccination coverage on the African continent.
METHODS: A prospective study was designed to consist of an online survey. It was distributed to 135 African otolaryngologists. Questions focussed on HPV vaccination programmes; whether they were government directed; and their rollout. Information from countries that had multiple otolaryngologists respond to the survey were compared. Additionally, data review and corroboration were performed.
RESULTS: There were 58 (43%) participants from 19 countries. Nine countries reported a national vaccination programme (NVP), five used Cervarix; four used quadrivalent Gardasil. Collateral data revealed 18 of 54 countries had NVP in Africa and 26 countries had completed HPV vaccine pilot or demonstration projects.
CONCLUSIONS: HPV vaccination in Africa should be urgently re-evaluated to include the HPV-6 and HPV-11 strains that cause JORRP, which have not been recognised during national vaccination programme planning.
METHODS: A prospective study was designed to consist of an online survey. It was distributed to 135 African otolaryngologists. Questions focussed on HPV vaccination programmes; whether they were government directed; and their rollout. Information from countries that had multiple otolaryngologists respond to the survey were compared. Additionally, data review and corroboration were performed.
RESULTS: There were 58 (43%) participants from 19 countries. Nine countries reported a national vaccination programme (NVP), five used Cervarix; four used quadrivalent Gardasil. Collateral data revealed 18 of 54 countries had NVP in Africa and 26 countries had completed HPV vaccine pilot or demonstration projects.
CONCLUSIONS: HPV vaccination in Africa should be urgently re-evaluated to include the HPV-6 and HPV-11 strains that cause JORRP, which have not been recognised during national vaccination programme planning.
摘要：
背景：复发性呼吸道乳头状瘤病（RRP）是由人乳头瘤病毒6（HPV-6）和HPV-11引起的慢性疾病，涉及呼吸道。疾病严重程度从轻度（声音嘶哑），到严重(喘鸣，呼吸窘迫和气道急症)。非洲是所有大陆中人口增长最快、最年轻的国家。它也是宫颈癌的最大负担。与致癌HPV毒株和负责RRP的毒株的感染有关。可以合理地得出结论，尽管中低收入国家的RRP可能被低估，它对非洲构成了相当大的健康风险。该项目的主要目的是评估非洲大陆HPV疫苗接种覆盖率的适用性。
方法：一项前瞻性研究由在线调查组成。它分发给135名非洲耳鼻喉科医生。问题集中在HPV疫苗接种计划;它们是否是政府指导的;以及它们的推出。比较了来自多个耳鼻喉科医师对调查做出回应的国家的信息。此外,进行了数据回顾和确证.
结果：来自19个国家的58名（43%）参与者。九个国家报告了国家疫苗接种计划（NVP），五个使用了Cervarix；四个使用了四价Gardasil。附带数据显示，54个国家中有18个在非洲有NVP，26个国家已经完成了HPV疫苗试点或示范项目。
结论：应紧急重新评估非洲的HPV疫苗接种，以包括引起JORRP的HPV-6和HPV-11菌株，在国家疫苗接种计划规划中没有得到承认。
方法：一项前瞻性研究由在线调查组成。它分发给135名非洲耳鼻喉科医生。问题集中在HPV疫苗接种计划;它们是否是政府指导的;以及它们的推出。比较了来自多个耳鼻喉科医师对调查做出回应的国家的信息。此外,进行了数据回顾和确证.
结果：来自19个国家的58名（43%）参与者。九个国家报告了国家疫苗接种计划（NVP），五个使用了Cervarix；四个使用了四价Gardasil。附带数据显示，54个国家中有18个在非洲有NVP，26个国家已经完成了HPV疫苗试点或示范项目。
结论：应紧急重新评估非洲的HPV疫苗接种，以包括引起JORRP的HPV-6和HPV-11菌株，在国家疫苗接种计划规划中没有得到承认。
